LIANY
LIANY clinical trials: LianBio
Every trial on ClinicalTrials.gov where LianBio is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LIANY on the catalyst calendar · LIANY registry changes
- Primary completion Mar 6, 2023ActualPhase 3NCT05174416A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMLianBio LLC · Obstructive Hypertrophic CardiomyopathyCompletedLIANYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2024ActualPhase 2NCT06206278Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaLianBio LLC · Gastric CancerTerminatedLIANYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2022ActualPhase 1NCT05135871Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese SubjectsLianBio LLC · Hypertrophic CardiomyopathyCompletedLIANYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 29, 2024ActualPhase 1NCT06032936BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR MutationsLianBio LLC · NSCLCTerminatedLIANYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 29, 2024ActualPhase 1NCT05621525Phase I Study of the BBP-398 in Patients With Advance Solid TumorsLianBio LLC · Advanced Solid TumorTerminatedLIANYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 15, 2023ActualPhase 3NCT05629390Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA StudyLianBio LLC · BlepharitisCompletedLIANYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2022Sponsor estimatePhase 2NCT05019794Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsLianBio LLC · Gastric CancerUnknown statusLIANYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner